505(b)(2) Pathway Fill Important Role in Generic's Future

Feb 27, 2014
By Applied Clinical Trials Editors

At last week's Generic Pharmaceutical Association (GPhA) annual meeting held in Orlando, a panel discussion was held with CEOs of top generic pharmaceutical companies and key financial analysts. Much of the discussion focused on the financial ramifications of fewer and lower-value small-molecule drugs coming off patent and being available for generic development. The consensus among the CEOs present seemed to be that 505(b)(2) products would fill an important role in their financial future. All of the CEO’s indicated a willingness to explore in-licensing where warranted.

Read the full release here.

lorem ipsum